What is CureTech's primary focus?

CureTech is a biotechnology company focused on cancer immunotherapy, developing immune-modulating products for the treatment and control of cancer.

What is the status of CureTech's operations?

CureTech is currently inactive, having ceased operations in February 2019.

When was CureTech founded?

CureTech was founded in January 2001.

What is CureTech's lead product?

CureTech's lead product is pidilizumab (CT-011), a humanized antibody in Phase II clinical testing.

Who acquired CureTech?

InSight Innovations acquired CureTech in 2018.

What was CureTech's total funding raised?

CureTech raised a total of $4,000,000 USD.

When did CureTech secure its last funding round and who participated?

CureTech secured its last funding round in September 2013, with participation from Clal Biotechnology Industries (CBI).

CureTech

Cancer Immunotherapy

Non Active, Feb 2019 ceased to operate

Seed Tel Aviv-Yafo, Israel Founded 2001

Website ↗ LinkedIn

Last updated 2026-06-18

Raised $4M funding round, Sep 2013

Total raised

$4.0M

Last: 2013-09

Stage

Seed

Founded

2001

Headcount

Tel Aviv-Yafo, Israel

Sector

—

About

CureTech is a biotechnology company developing broad-spectrum, immune-modulating products for the treatment and control of cancer. Its product line includes antibodies and peptide-based vaccines designed to modulate the immune response, allowing it to exert its anti-cancer activity in an effective manner. CureTech's lead humanized antibody product, pidilizumab (CT-011), is in Phase II clinical testing. Pidilizumab has shown promising results in attenuating tumor growth and eliminating tumor metastases in a variety of model systems. Several patents and pending patent applications worldwide protect the company's products. A licensing agreement for further development and commercialization of pidilizumab was signed with Medivation in 2014. In 2018, InSight Innovations acquired CureTech.

Funding history · 1 round · $4.0M total

2013-09

$4.0M

Clal Biotechnology Industries (CBI)

Q&A

What is CureTech's primary focus?: CureTech is a biotechnology company focused on cancer immunotherapy, developing immune-modulating products for the treatment and control of cancer.
What is the status of CureTech's operations?: CureTech is currently inactive, having ceased operations in February 2019.
When was CureTech founded?: CureTech was founded in January 2001.
What is CureTech's lead product?: CureTech's lead product is pidilizumab (CT-011), a humanized antibody in Phase II clinical testing.
Who acquired CureTech?: InSight Innovations acquired CureTech in 2018.
What was CureTech's total funding raised?: CureTech raised a total of $4,000,000 USD.
When did CureTech secure its last funding round and who participated?: CureTech secured its last funding round in September 2013, with participation from Clal Biotechnology Industries (CBI).
How many employees did CureTech have?: CureTech had 51-200 employees.

Team · 1

Lior Carmon

Founder · Founder

LinkedIn ↗

Sectors & technology

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

Biologicals

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business model

B2B

External links

Website	curetechbio.com
LinkedIn	linkedin.com/company/7018637

Identifiers & details

Founded	2001-1
Employees (exact)	97
Status reason	Non Active, Feb 2019 ceased to operate